Xiangqun Fang

Xiangqun Fang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2023 in Journal of Intensive Medicine
Verified
Journal Article
Open access
YLYanxin Liu
Yanxin Liu
JWJiang Wang
Jiang Wang
TLTingting Liu
Tingting Liu
KXKun Xiao
Kun Xiao
PYPeng Yan
Peng Yan
Lixin XieLixin Xie
Lixin Xie
Linezolid-associated thrombocytopenia (LAT) leads to drug withdrawal associated with a poor prognosis. Some risk factors for LAT have been identified; however, the sample size of previous studies was small, data from elderly individuals are limited, and a simple risk score scale was not established to predict LAT at an early stage, making it difficult to identify and intervene in LAT at an early stage. In this single-center retrospective case-control study, we enrolled elderly patients treated with linezolid in the intensive care unit from January 2015 to December 2020. All the data of enrolled patients, including demographic information and laboratory findings at baseline, were collected. We analyzed the incidence and risk factors for LAT and established a nomogram risk prediction model for LAT in the elderly population. A total of 428 elderly patients were enrolled, and the incidence of LAT was 35.5% (152/428). Age ≥80 years old (OR=1.980; 95% CI: 1.179–3.325; P=0.010), duration of linezolid ≥ 10 days (OR=1.100; 95% CI: 1.050–1.152; P <0.0001), platelet count at baseline (100–149×109/L vs. ≥200×109/L, OR=8.205, 95% CI: 4.419–15.232, P <0.0001; 150–199 ×109/L vs. ≥200×109/L, OR=3.067, 95% CI: 1.676–5.612, P <0.001), leukocyte count at baseline ≥16×109/L (OR=2.580; 95% CI: 1.523–4.373; P <0.0001), creatinine clearance <50 mL/min (OR=2.323; 95% CI: 1.388–3.890; P=0.001), and total protein <60 g/L (OR=1.741; 95% CI: 1.039–2.919; P=0.035) were associated with LAT. The nomogram prediction model called “ADPLCP” (age, duration, platelet, leukocyte, creatinine clearance, protein) was established based on logistic regression. The area under the curve (AUC) of ADPLCP was 0.802 (95% CI: 0.748–0.856; P <0.0001), with 78.9% sensitivity and 69.2% specificity (cut-off was 108). Risk stratification for LAT was performed based on “ADPLCP.” Total points of <100 were defined as low risk, and the possibility of LAT was 150 was defined as high risk, and the probability of LAT was >67.5%. We created the ADPLCP risk score scale to predict the occurrence of LAT in elderly individuals. ADPLCP is simple and feasible and is helpful for the early determination of LAT to guide drug withdrawal or early intervention.

10 March 2025 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
TLTingting Liu
Tingting Liu
JWJionghe Wu
Jionghe Wu
XFXiangqun Fang
Xiangqun Fang
Lixin XieLixin Xie
Lixin Xie
HLHongxia Li
Hongxia Li

18 July 2024 in Intensive Care Research
Verified
Journal Article
Open access
PDF file
YLYanxin Liu
Yanxin Liu
TLTingting Liu
Tingting Liu
KXKun Xiao
Kun Xiao
JWJiang Wang
Jiang Wang
PYPeng Yan
Peng Yan
Lixin XieLixin Xie
Lixin Xie
Background: Patients with severe infection often require careful fluid management. Intravenous linezolid can increase the fluid volume, whereas oral linezolid can effectively limit the fluid volume. However, the differences in the treatment effect and incidence of thrombocytopenia between oral and intravenous linezolid in patients with severe infection remain unclear. Methods: Patients who received linezolid in the intensive care unit of PLA General Hospital from December 2010 to December 2020 were divided into an oral group and intravenous group according to the route of administration, and we further established the PO group and PO-match group by propensity score matching. The anti-infection effect of linezolid and incidence of thrombocytopenia were compared between the two groups. Results: In total, 177 patients were enrolled in the study (59 in PO group and 118 in PO-match group). The microbial clearance rate and clinical cure rate were similar between the two groups (70.0% vs. 79.3%, P = 0.293; 72.9% vs. 83.9%, P = 0.213). The 30-day mortality rate was slightly higher in the PO group than in the PO-match group, but the difference was not statistically significant (13.6% vs. 6.8%, P = 0.138). There was no difference in the incidence of thrombocytopenia between the two groups (62.7% vs. 65.3%, P = 0.739). Conclusions: There were no significant differences in the treatment effect or incidence of thrombocytopenia between oral and intravenous administration of linezolid in patients with severe infection.

4 June 2024 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
TLTingting Liu
Tingting Liu
JWJionghe Wu
Jionghe Wu
PNPeng Na
Peng Na
XWXia Wu
Xia Wu
YYYaping Yuan
Yaping Yuan
HLHongxia Li
Hongxia Li
Many older adult patients receive low-dose teicoplanin with varied regimens, leading to a lack of clarity on its optimal regimens and toxicity profiles in China. This study aimed to clarify these aspects by analyzing teicoplanin treatment concentrations and toxicities. We included older adult patients administered teicoplanin at four tertiary hospitals in Beijing from June 2021 to July 2023, targeting a trough concentration (Cmin) ≥ 10 mg/L. Teicoplanin concentrations and toxicities were monitored dynamically. From 204 patients, we obtained 632 teicoplanin concentrations. Most patients (83.3%) received low-dose regimens. Suboptimal concentrations were found in 66.4% of patients within 7 days of treatment and 17.0% after 15 days. Cmin gradually increased with treatment duration and was influenced initially by creatinine and by both body weight and creatinine from days 8 to 14. The target concentration was achieved in 53.1%, 33.9%, 15.6%, and 5.5% of patients at 3, ≤ 7, 8–14, and ≥ 15 days after withdrawal, respectively. Slow elimination was associated with average Cmin and eGFR. Nephrotoxicity, hepatotoxicity, and thrombocytopenia occurred in 12.5%, 4.1%, and 31.5% of patients, respectively, without significant differences between concentrations. Most older adult patients were underdosed, indicating a need for dose adjustment. Given the varied risk factors for suboptimal concentrations in different treatment stages, a one-size-fits-all regimen was ineffective. We recommend an initial dose of 400 mg at 12-h intervals for the first three days, with subsequent doses from days 4 to 14 adjusted based on creatinine and body weight; after day 14, a maintenance dose of 200 mg daily is advised. ChiCTR2100046811; 28/05/2021.

6 August 2025 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
BLBing Liu
Bing Liu
GGGuangrui Geng
Guangrui Geng
TLTingting Liu
Tingting Liu
LZLingli Zhou
Lingli Zhou
FWFang Wang
Fang Wang
HLHongxia Li
Hongxia Li
Background: The relationships of renal function with linezolid trough concentration (C min ) and hematological toxicity have not been clarified in elderly patients. Methods: In this propensity-matched cohort analysis, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and March 2024 were included. The patients were grouped by renal function and propensity score matching (PSM) was used to balance baseline characteristics. Linezolid C min and hematological indices were monitored dynamically. Results: Among 320 patients, 152 were eventually enrolled after PSM, including 56 (36.8%) patients with normal renal function (RN) and 96 (63.2%) patients with renal dysfunction (RD). C min at 3–5 (12.5 mg/L vs. 21.2 mg/L, P = 0.001) and 6–10 days (14.8 mg/L vs. 27.4 mg/L, P < 0001) was significantly lower in the RN group. The risk of linezolid-associated thrombocytopenia (LAT) and linezolid-associated anemia (LAA) in the RD group was 4.485 folds and 2.308 folds higher than in the RN group. The decreases in hematological indices were significantly higher in RD group than in RN group. Conclusions: Renal function significantly affected linezolid C min and hematological toxicity, and the dose of linezolid should be reduced in elderly patients with renal dysfunction. Trial registration: ChiCTR2100045707; Registration Date: 23/04/2021.

1 February 2026 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
TLTingting Liu
Tingting Liu
ZLZeyang Li
Zeyang Li
GWGe Wei
Ge Wei
YYYang Yang
Yang Yang
FWFang Wang
Fang Wang
XFXiangqun Fang
Xiangqun Fang
Background: Elderly patients are at increased risk of infection with methicillin-resistant Staphylococcus aureus (MRSA). Therefore, this article comprehensively reviews the progress in therapeutic drug monitoring (TDM) and pharmacokinetic (PK) studies of linezolid, contezolid and tedizolid in the elderly population, to inform individualized dosing strategies. Methods: This review synthesized evidence from published and ongoing studies examining the TDM and PK studies of linezolid, contezolid and tedizolid in elderly patients, encompassing investigations into drug concentrations monitoring, PK parameters, and population PK studies. No date restrictions were applied to the study selection. Results: The distinct pathophysiology of elderly patients leads to significant alterations in the PK characteristics of various antibacterial agents, necessitating individualized dosage adjustments. In this population, linezolid exhibits a prolonged half-life, markedly decreased clearance, and elevated risk of severe overexposure. Therefore, its dosage requires adjustment based on renal function and age. Contezolid exhibits comparable pharmacokinetics in patients aged 65– 74 years to younger adults; however, in patients aged 80 and above, its time to peak concentration is delayed, elimination is accelerated, while Cmax and AUC0-t increase dose-dependently. Tedizolid plasma exposure was similar in elderly and younger control subjects, indicating that no dose adjustment was warranted for elderly subjects. Moreover, contezolid and tedizolid exhibit a more favorable safety profile compared with linezolid. Conclusion: The PK characteristics of oxazolidinone antibiotics may be altered in the elderly population. TDM and model-informed precision dosing (MIPD) are crucial approaches for achieving individualized dosing strategies.